Advertisement

Pharmacy World & Science

, Volume 32, Issue 6, pp 707–710 | Cite as

Cost reduction associated with restriction policy on dispensing intravenous esomeprazole in lebanon

  • Soumana C. NasserEmail author
  • Jeanette G. Nassif
  • Fouad Mahfouz
Short Research Report

Abstract

Objectives To assess the impact of the pharmacist on cost through simple implementation of restriction policy on IV drug usage during pharmacy dispensing procedure. Setting In-patient floors of a Hospital. Methods All medication orders for IV esomeprazole, received at the pharmacy during a 24-month period, were reviewed for appropriate IV route of administration. Two separate time intervals, pre- and post- implementation of restriction dispensing policy, were used to determine cost impact of pharmacy intervention. Main Outcome Measure The cost difference between pre- and post-restriction periods. Results During the pre-restriction period, the majority of esomeprazole IV vials were dispensed to patients able to tolerate oral medications and who were admitted to non-intensive care units. The average monthly consumption of IV esomeprazole was 1,439 vials in the pre-restriction period as compared to 346 vials in the post-restriction period. Therefore, the associated cost was reduced by an average of $21,233 per month. Conclusion Even though the clinical role of pharmacy practice in Middle Eastern countries is limited, this study highlighted the impact of the pharmacist on cost through the implementation of restriction policy during dispensing procedure, leading to a cost reduction by four folds.

Keywords

Drug costs Esomeprazole Hospital pharmacy Intravenous drug administration Lebanon 

Notes

Funding

The authors would like to thank the Lebanese American University for the financial support in conducting this study.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    George CJ, Korc B, Ross JS. Appropriate Proton Pump Inhibitor Use Among Older Adults: a Retrospective Chart Review. Am Geriatr Pharmacother. 2008;6:249–54.CrossRefGoogle Scholar
  2. 2.
    Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103(5):327–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitos. Digestion. 2004;70:250–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Metz DC, Miner PB, Heuman DM, et al. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastroesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:813–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosh’s KM, Bondarov P, Lundgren M, et al. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides a similar level of acid control as oral administration in healthy subjects [abstract no. S1611]. Gastroenterology. 2003;124(4 Suppl. 1):A231.Google Scholar
  6. 6.
    Keating GM, Figgit DP. Intravenous esomeprazole. Drugs. 2004;64(8):875–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci. 2008;54(9):1947–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Zeigler AJ, McAllen KJ, Slot MG, Barletta JF. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis. Ann Pharmacother. 2008;42(7):940–6. doi: 10.1345/aph.1L123.CrossRefPubMedGoogle Scholar
  9. 9.
    Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm. 2008;14(9):831–43.PubMedGoogle Scholar
  10. 10.
    Ramser KL, Sprabery LR, Hamann GL, George CM, Will A. Results of an intervention in an academic internal medicine clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change. J Manag Care Pharm. 2009;15(4):344–50.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Soumana C. Nasser
    • 1
    Email author
  • Jeanette G. Nassif
    • 2
  • Fouad Mahfouz
    • 3
  1. 1.School of PharmacyLebanese American UniversityByblosLebanon
  2. 2.School of PharmacyLebanese American UniversityByblosLebanon
  3. 3.Pharmacy DepartmentNotre Dames De Secours HospitalByblosLebanon

Personalised recommendations